- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00627731
Oral Glucocorticosteroid in the Treatment of Severe Asthma Exacerbation in Hospitalized Patients
September 5, 2011 updated by: Naoki Inui, Hamamatsu University
Phase 4, Randomized Study of Oral Glucocorticosteroid Administration in the Treatment of Acute Severe Asthma Exacerbation in Hospitalized Patients
A comparison of oral prednisolone administration with intravenous methylprednisolone infusion in the treatment of acute asthma exacerbation in hospitalized patients.
Oral glucocorticosteroids administration may be effective as intravenous high-dose methylprednisolone infusion.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hamamatsu, Japan
- Hamamatsu University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 80 years (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Asthma patients, who need hospitalized treatment, who do not respond with initial treatment including bronchodilator and IV methylprednisolone therapy
Exclusion Criteria:
- Need for incubation
- With severe complications
- Received systemic glucocorticosteroid therapy in the previous 4 weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 1
mPSL 240 mg per day for 5 days
|
mPSL IV 240mg per day for 5 days and oral PSL 40mg per day for 5 days
Other Names:
|
EXPERIMENTAL: 2
PSL 40mg per day for 10 days
|
PSL 40 mg per day for 10 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy of oral prednisolone for the treatment of acute asthma
Time Frame: three-year
|
three-year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The safety of oral prednisolone for the treatment of acute asthma
Time Frame: three-year
|
three-year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2007
Primary Completion (ACTUAL)
October 1, 2009
Study Completion (ACTUAL)
October 1, 2009
Study Registration Dates
First Submitted
February 22, 2008
First Submitted That Met QC Criteria
February 29, 2008
First Posted (ESTIMATE)
March 3, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
September 7, 2011
Last Update Submitted That Met QC Criteria
September 5, 2011
Last Verified
October 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Prednisolone
- Methylprednisolone Acetate
- Methylprednisolone
- Methylprednisolone Hemisuccinate
- Prednisolone acetate
- Prednisolone hemisuccinate
- Prednisolone phosphate
Other Study ID Numbers
- Hamamatsu-18-68
- Hamamatsu-1968
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on methylprednisolone sodium succinate (mPSL)
-
Fundação de Medicina Tropical Dr. Heitor Vieira...CompletedSARS-CoV Infection | Severe Acute Respiratory Syndrome (SARS) PneumoniaBrazil
-
National Cancer Center, KoreaCompletedPostoperative Complications | Acute Respiratory Distress Syndrome | Acute Lung InjuryKorea, Republic of
-
Biotech Pharmaceutical Co., Ltd.Recruiting
-
Taipei Medical University WanFang HospitalRecruiting
-
Louisiana State University Health Sciences Center...UnknownIntractable Epilepsy | Convulsive SeizuresUnited States
-
Massachusetts Eye and Ear InfirmaryCompletedSafety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host DiseaseOcular GVHDUnited States
-
Queen Elizabeth Hospital, Hong KongCompletedOsteoarthritis, KneeHong Kong
-
Hospital Sao DomingosTerminatedCovid-19 | Cytokine Release SyndromeBrazil
-
Massachusetts Eye and Ear InfirmaryNational Institute on Deafness and Other Communication Disorders (NIDCD)Completed
-
King Saud UniversitySaudi Society of Dermatology and Dermatologic surgeryCompletedAlopecia Totalis | Alopecia Universalis | Ophiasic AlopeciaSaudi Arabia